1. W. M. O'Brien,Indomethacin: survey of clinical trials Clin. Pharmacol. Exp. Ther.9, 94–107 (1968).
2. R. H. Gifford,Chemotherapy of rheumatoid arthritis. Ration. Drug. Ther.7, 1–7 (1973).
3. H.-D. Dell, M. Doersing, W. Fisher, H. Jacobi and R. Kamp,Biochemical studies on acemetacin. Arzneim.-Forsch.30, 1371–1383 (1980).
4. T. Y. Shen,Towards more selective NSAID. Eur. J. Rheumatol. Inflammation1, 167–172 (1978).
5. I. Tanaka, H. Yoshizumi, Y. Tanaka, S. Takeda, C. Kamei, N. Nakaya, K. Kitazumi, H. Tagami and K. Tasaka,Pharmacological profiles of 2-carboxyphenyl-1-(4chlorobenzoyl)-5-methoxy-2-methyl-indol-3-acetate and 2-[(2-Carboxyphenoxy)-carbonyl]phenyl-l-(4chlorobenzoyl)-5-methoxy-2-methylindol-3-acetate, a new antiinflammatory agent. Arzneim.-Forsch/Drug Res.36, 703–709 (1986).